14 research outputs found
Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study
Background and Objective: Early-onset Parkinson's disease (EOPD) commonly recognizes a genetic basis; thus, patients with EOPD are often addressed to diagnostic testing based on next-generation sequencing (NGS) of PD-associated multigene panels. However, NGS interpretation can be challenging in a diagnostic setting, and few studies have addressed this issue so far. Methods: We retrospectively collected data from 648 patients with PD with age at onset younger than 55 years who underwent NGS of a minimal shared panel of 15 PD-related genes, as well as PD-multiplex ligation-dependent probe amplification in eight Italian diagnostic laboratories. Data included a minimal clinical dataset, the complete list of variants included in the diagnostic report, and final interpretation (positive/negative/inconclusive). Patients were further stratified based on age at onset â€40 years (very EOPD, n = 157). All variants were reclassified according to the latest American College of Medical Genetics and Genomics criteria. For classification purposes, PD-associated GBA1 variants were considered diagnostic. Results: In 186 of 648 (29%) patients, the diagnostic report listed at least one variant, and the outcome was considered diagnostic (positive) in 105 (16%). After reanalysis, diagnosis changed in 18 of 186 (10%) patients, with 5 shifting from inconclusive to positive and 13 former positive being reclassified as inconclusive. A definite diagnosis was eventually reached in 97 (15%) patients, of whom the majority carried GBA1 variants or, less frequently, biallelic PRKN variants. In 89 (14%) cases, the genetic report was inconclusive. Conclusions: This study attempts to harmonize reporting of PD genetic testing across several diagnostic labs and highlights current difficulties in interpreting genetic variants emerging from NGS-multigene panels, with relevant implications for counseling. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Author Correction: Elucidating causative gene variants in hereditary Parkinsonâs disease in the Global Parkinsonâs Genetics Program (GP2)
Correction to: npj Parkinsonâs Disease, published online 27 June 2023 In this article the Global Parkinsonâs Genetics Program (GP2) members names and affiliations were missing in the main author list of the Original article which are listed in the below
Author Correction: Elucidating causative gene variants in hereditary Parkinsonâs disease in the Global Parkinsonâs Genetics Program (GP2)
Correction to: s41531-023-00526-9 npj Parkinsonâs Disease, published online 27 June 2023 In this article the Global Parkinsonâs Genetics Program (GP2) members names and affiliations were missing in the main author list of the Original article which are listed in the below
Elucidating causative gene variants in hereditary Parkinsonâs disease in the Global Parkinsonâs Genetics Program (GP2)
Abstract The Monogenic Network of the Global Parkinsonâs Genetics Program (GP2) aims to create an efficient infrastructure to accelerate the identification of novel genetic causes of Parkinsonâs disease (PD) and to improve our understanding of already identified genetic causes, such as reduced penetrance and variable clinical expressivity of known disease-causing variants. We aim to perform short- and long-read whole-genome sequencing for up to 10,000 patients with parkinsonism. Important features of this project are global involvement and focusing on historically underrepresented populations